Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
OneChain Immunotherapeutics logo — Development of CAR-T candidates for the treatment of acute l...

OneChain Immunotherapeutics

Development of CAR-T candidates for the treatment of acute lymphoblastic leukemia and other hematological malignancies.

Founded 2020 21 employees Seed Total: $6.70M Biotechnology, Life Sciences

General Information

Company Name OneChain Immunotherapeutics
Founded Year 2020
Founders / Decision Makers
Team member
Employees 21
Industries Biotechnology, Life Sciences
Funding Stage Seed
Business Model B2B, B2C, B2D
Revenue Model Licensing, Product Sales
Social

BounceWatch is an independent company data service, not affiliated with OneChain Immunotherapeutics. To contact OneChain Immunotherapeutics, visit onechaintx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does OneChain Immunotherapeutics compare?

A PDF of OneChain Immunotherapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting OneChain Immunotherapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About OneChain Immunotherapeutics

OneChain Immunotherapeutics, founded in 2020, is a promising player in the Biotechnology and Life Sciences sectors. This spin-off from the Josep Carreras Leukemia Research Institute and ICREA focuses on developing CAR-T candidates for treating acute lymphoblastic leukemia and other hematological malignancies. The company leverages the expertise of Dr. Pablo Menéndez in targeting multiple antigens within these disorders.

Recently, OneChain Immunotherapeutics secured a €6.70M Seed Round investment on 22 June 2023. The funding was led by notable investors including Nara Capital, Clave Capital, the Centre for the Development of Industrial Technology (CDTI), Invivo Capital Partners, and the Josep Carreras Leukaemia Research Institute.

While its headquarters remain unspecified, the company's strategic focus and robust backing underscore its potential impact in the field of hematological cancer treatment.

Business keywords: CAR-T Therapy, Hematological Malignancies, Acute Lymphoblastic Leukemia, Immunotherapy, Personalized Medicine, Leukemia Research, Antigen Targeting, Biomedicine, Innovation, Research and Development, Spin-off Company, Institute Collaboration, Hematology, Oncology

Services & Products

Development of CAR-T candidates
Clinical Studies

Target Customers

Cancer Patients Healthcare Providers Research Institutions

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Seed €6.70M 5
Invivo Partners Nara Capital Clave Capital
Invivo Partners, Nara Capital +3
01 Jun 2023
Spinout Undisclosed 2
Josep Carreras Leukaemia Research Institute
Josep Carreras Leukaemia Research Institute, ICREA
01 Jan 2020

OneChain Immunotherapeutics Alternatives & Competitors

View All Alternatives
OneChain Immunotherapeutics vs
Arcellx
Arcellx United States

Arcellx is a clinical-stage biotechnology company based in Redwood City, California

Acquired
121 employees
Biopharma, Biotechnology
OneChain Immunotherapeutics vs
Epitopea
Epitopea Canada

Exploiting a new class of tumour specific antigens for cancer therapy

Seed
50 employees
Biotechnology, Health and Wellness
OneChain Immunotherapeutics vs
LAVA Therapeutics N.V.
LAVA Therapeutics N.V. The Netherlands

Developing next generation bispecific gamma-delta T cell engaging (bsTCE) antibodies to fight cancer

Acquired
7 employees
Biotechnology, Life Sciences
View all alternatives

FAQ About OneChain Immunotherapeutics

Development of CAR-T candidates for the treatment of acute lymphoblastic leukemia and other hematological malignancies.
OneChain Immunotherapeutics was founded in 2020.
OneChain Immunotherapeutics operates in Biotechnology and Life Sciences. Its work centres on CAR-T Therapy, Hematological Malignancies, Acute Lymphoblastic Leukemia and Immunotherapy. Its customers include Cancer Patients, Healthcare Providers and Research Institutions.
OneChain Immunotherapeutics has a B2B, B2C and B2D business model. Its revenue comes from Licensing and Product Sales.
OneChain Immunotherapeutics has approximately 21 employees.
OneChain Immunotherapeutics has completed 2 funding rounds, raising a total of $6.70M. The latest funding stage is Seed.
OneChain Immunotherapeutics offers: Development of CAR-T candidates, Clinical Studies.
Top alternatives and competitors to OneChain Immunotherapeutics include Arcellx, Epitopea, LAVA Therapeutics N.V., Vect-Horus, Laminar Pharma. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
OneChain Immunotherapeutics and Arcellx are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for OneChain Immunotherapeutics, https://bouncewatch.com/company/onechain, updated 11 March 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout